Showing 71-80 of 5643 results for "".
Dental Turf War Sounds Familiar
https://modernod.com/articles/significant-findings/dental-turf-war-sounds-familiar/37788/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatPatients With Certain Lipids May Be at High Risk of Developing POAG
https://modernod.com/articles/significant-findings/patients-with-certain-lipids-may-be-at-high-risk-of-developing-poag/37749/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatThe Need to Define Advocacy Within Optometry
https://modernod.com/topics/health-policy/the-need-to-define-advocacy-within-optometry/38678/Where major health-related organizations stand on the question of advocacy. Part two of a multi-part series.First Myopia Drug Approved in Europe
https://modernod.com/podcasts/eyewire-news-the-podcast/first-myopia-drug-approved-in-europe/37088/The first pharmaceutical treatment for myopia is approved in Europe; the FDA sets a target action date for a first-of-its-kind presbyopia drop; and John Berdahl, MD, discusses the reimbursement landscape in ophthalmology. Learn more about your ad choices. Visit megaphone.fm/adchoicesAlcon Acquires LumiThera
https://modernod.com/podcasts/eyewire-news-the-podcast/alcon-acquires-lumithera/37092/Alcon makes a major acquisition to bolster is vitreoretinal surgery portfolio; the European Commission (EC) approves Eylea 8 mg for extended treatment intervals; and Eric Donnenfeld, MD, discusses the business of myopia management. Learn more about your ad choices. Visit megaphone.fm/adchoicesB+L Launches New Scleral Lenses Technology
https://modernod.com/podcasts/eyewire-news-the-podcast/bl-launches-new-scleral-lenses-technology/37085/B+L launches a new scleral lenses technology in the US; New World Medical introduces a transparent tip on its Streamline Surgical System, and an OCT platform is cleared in Europe. Learn more about your ad choices. Visit megaphone.fm/adchoicesFDA Issues CRL to Regeneron for Eylea HD Extended Dosing
https://modernod.com/podcasts/eyewire-news-the-podcast/fda-issues-crl-to-regeneron-for-eylea-hd-extended-dosing/37081/The FDA responds to Regeneron’s request to extend dosing intervals for Eylea HD; Regeneron applies for a new indication for Eylea HD; and several recent executive appointments are announced in the ophthalmology industry. Learn more about your ad choices. Visit megaphone.fm/adchoicesHaag-Streit Launches METIS 900 Microscope
https://modernod.com/podcasts/eyewire-news-the-podcast/haag-streit-launches-metis-900-microscope/37074/Haag-Streit launches the METIS 900 ophthalmic microscope system; the FDA accepts Glaukos’ NDA for Epi-on cross-linking; and Optos releases its next generation ultra-widefield SLO imaging technology. Learn more about your ad choices. Visit megaphone.fm/adchoicesNew Myopia Software on Pentacam AXL
https://modernod.com/podcasts/eyewire-news-the-podcast/new-myopia-software-on-pentacam-axl/37073/Oculus launches new myopia software on its Pentacam AXL; the first clinical polygenic risk score test for glaucoma in the US is launched; and Virtual Vision Health releases visual acuity testing on its VR platform Learn more about your ad choices. Visit megaphone.fm/adchoicesFDA Approves Genentech's Susvimo Ocular Implant for DME
https://modernod.com/podcasts/eyewire-news-the-podcast/fda-approves-genentechs-susvimo-ocular-implant-for-dme/37070/The FDA approves a label expansion for Genentech’s Susvimo implant; Iantrek completes the first commercial cases of its C.Rex micro-interventional system; and there are several executive leadership announcements made in ophthalmology. Learn more about your ad choices. Visit megaphone.fm/adchoices